LatestLicenses And Certifications 27 September 2026
India MSME & Pharma Updates: Trademark Rules, Udyam Bill, Cancer Drug Withdrawal
India sees key developments across its MSME and pharmaceutical sectors. Updated trademark registration guidelines aim to help startups and MSMEs navigate brand protection, while the Micro, Small and Medium Enterprises Development (Amendment) Bill, 2026 refines the Udyam registration framework. Meanwhile, Daiichi Sankyo and Merck have withdrawn their accelerated approval application for a lung cancer biologic, signaling a pause in that pipeline.
Trademark Registration Updates
- New guidelines simplify the filing process for startups and MSMEs. Details and practical tips are available here.
Udyam Registration Bill 2026
- The amendment aligns the MSMED Act with current business needs and expands formal recognition via the Udyam portal. Full text can be read here.
Lung Cancer Drug Application Withdrawal
- Daiichi Sankyo and Merck have voluntarily withdrawn their Biologics License Application seeking accelerated approval. The announcement is reported here.
Need help understanding this update?
Connect with our domain experts instantly via WhatsApp for customized legal guidance.